Argenica Therapeutics Ltd: Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
Argenica Therapeutics Ltd: Appendix 4G & Corporate Governance Statement
Argenica Therapeutics Ltd: Change of Director's Interest Notice
Argenica Therapeutics Ltd: Change of Director's Interest Notice x3
Argenica Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Argenica Therapeutics Ltd: Phase 2 Stroke Clinical Trial Update
Argenica Therapeutics Ltd: Investor Webinar Presentation
Argenica Therapeutics Ltd: Final Director's Interest Notice
Argenica Therapeutics Ltd: Change of Director's Interest Notice
Argenica Therapeutics Ltd: ARG-007 Reduces Effects of TBI in Preclinical Study
Argenica Therapeutics Ltd: DSMB Confirms Safety of First Patients Dosed
Argenica Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Argenica Therapeutics Ltd: Trading Halt
Argenica Therapeutics Ltd: Patient Dosing Milestone Achieved in Phase 2 Stroke Trial
Argenica Therapeutics Ltd: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
Argenica Therapeutics Ltd: FDA Grants Rare Pediatric Disease Designation For HIE
Argenica Therapeutics Ltd: Phase 2 Manufacturing Completed & Trial Update
Argenica Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Argenica Therapeutics Ltd: Phase 2 Stroke Clinical Trial Update
Argenica Therapeutics Ltd: Initial Director's Interest Notice
No Data